Capital and pipeline double anchored, Sac-TMT becomes the "ballast stone" of Merck's global pipeline.

According to the Wise Finance APP, on November 4th, Merck (MRK.US) announced that it has reached a $700 million R&D funding agreement with Blackstone, and the funds will be used for the global development of its core ADC asset sacituzumab govitecan (sac-TMT). As ADCs become a global focus of pharmaceutical innovation, multinational pharmaceutical companies and capital giants joining forces for special development not only reflects a high recognition of the commercial value of sac-TMT, but also signifies that Chinese innovative drugs are accelerating their impact on the global blockbuster drug camp through the dual driving forces of "global R&D + capital empowerment".